Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

7,979 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Withdrawing Ixekizumab in Patients With Psoriatic Arthritis Who Achieved Minimal Disease Activity: Results From a Randomized, Double-Blind Withdrawal Study.
Coates LC, Pillai SG, Tahir H, Valter I, Chandran V, Kameda H, Okada M, Kerr L, Alves D, Park SY, Adams DH, Gallo G, Hufford MM, Hojnik M, Mease PJ, Kavanaugh A; SPIRIT-P3 Study Group. Coates LC, et al. Among authors: park sy. Arthritis Rheumatol. 2021 Sep;73(9):1663-1672. doi: 10.1002/art.41716. Epub 2021 Aug 6. Arthritis Rheumatol. 2021. PMID: 33682378 Free PMC article.
Efficacy and safety of infliximab plus naproxen versus naproxen alone in patients with early, active axial spondyloarthritis: results from the double-blind, placebo-controlled INFAST study, Part 1.
Sieper J, Lenaerts J, Wollenhaupt J, Rudwaleit M, Mazurov VI, Myasoutova L, Park S, Song Y, Yao R, Chitkara D, Vastesaeger N; All INFAST Investigators. Sieper J, et al. Ann Rheum Dis. 2014 Jan;73(1):101-7. doi: 10.1136/annrheumdis-2012-203201. Epub 2013 May 21. Ann Rheum Dis. 2014. PMID: 23696633 Free PMC article. Clinical Trial.
Maintenance of biologic-free remission with naproxen or no treatment in patients with early, active axial spondyloarthritis: results from a 6-month, randomised, open-label follow-up study, INFAST Part 2.
Sieper J, Lenaerts J, Wollenhaupt J, Rudwaleit M, Mazurov VI, Myasoutova L, Park S, Song Y, Yao R, Chitkara D, Vastesaeger N; All INFAST Investigators. Sieper J, et al. Ann Rheum Dis. 2014 Jan;73(1):108-13. doi: 10.1136/annrheumdis-2013-203460. Epub 2013 Jun 5. Ann Rheum Dis. 2014. PMID: 23740231 Free PMC article. Clinical Trial.
Efficacy and safety of ixekizumab in patients with active psoriatic arthritis with and without concomitant conventional disease-modifying antirheumatic drugs: SPIRIT-P1 and SPIRIT-P2 3-year results.
Coates LC, Mease P, Kronbergs A, Helt C, Sandoval D, Park SY, Combe B, Nash P, Deodhar A. Coates LC, et al. Among authors: park sy. Clin Rheumatol. 2022 Oct;41(10):3035-3047. doi: 10.1007/s10067-022-06218-8. Epub 2022 Jun 8. Clin Rheumatol. 2022. PMID: 35674861 Free PMC article. Clinical Trial.
Correction to: Efficacy and safety of ixekizumab in patients with active psoriatic arthritis with and without concomitant conventional disease-modifying antirheumatic drugs: SPIRIT-P1 and SPIRIT-P2 3-year results.
Coates LC, Mease P, Kronbergs A, Helt C, Sandoval D, Park SY, Combe B, Nash P, Deodhar A. Coates LC, et al. Among authors: park sy. Clin Rheumatol. 2022 Oct;41(10):3261. doi: 10.1007/s10067-022-06271-3. Clin Rheumatol. 2022. PMID: 35821169 Free PMC article. No abstract available.
Recapture and retreatment rates with ixekizumab after withdrawal of therapy in patients with axial spondyloarthritis: results at week 104 from a randomised placebo-controlled withdrawal study.
Landewé RBM, Poddubnyy D, Rahman P, Van den Bosch FE, Bolce R, Liu Leage S, Lisse JR, Park SY, Gensler L. Landewé RBM, et al. Among authors: park sy. Ann Rheum Dis. 2023 Feb;82(2):212-216. doi: 10.1136/ard-2022-222731. Epub 2022 Sep 13. Ann Rheum Dis. 2023. PMID: 36100350 Free PMC article. Clinical Trial.
IL17A Blockade with Ixekizumab Suppresses MuvB Signaling in Clinical Psoriasis.
Ochsner SA, Pedroza M, Pillich RT, Krishnan V, Konicek BW, Dow ER, Park SY, Agarwal SK, McKenna NJ. Ochsner SA, et al. Among authors: park sy. J Invest Dermatol. 2023 Sep;143(9):1689-1699. doi: 10.1016/j.jid.2023.03.1658. Epub 2023 Mar 24. J Invest Dermatol. 2023. PMID: 36967086 Free article.
7,979 results